In a recent study, Li et al. [154] reported how CXCR2 expression is associated with prostate cancer progression and tumor grade and described how its blockade may serve as a viable approach to overcome the challenges of treating advanced therapy-resistant and metastatic prostate cancers. The gene discussed is CXCR2; the disease is prostate cancer.